Lysophosphatidylcholine potentiates vascular contractile responses in rat aorta via activation of tyrosine kinase.
We previously reported that while lysophosphatidylcholine (LPC) does not itself produce contraction, it significantly potentiates the contractile responses induced by high-K(+), UK14,304 (a selective alpha(2)-adrenoceptor agonist) and phorbol ester in the endothelium-denuded rat aorta. To further investigate this phenomenon, we examined the effects of genistein and tyrphostin B42 (both tyrosine kinase inhibitors) on the LPC-induced potentiation of the contractile responses to high-K(+) and UK14,304 in the endothelium-denuded rat aorta. Although genistein (3 x 10(-6) M, 10(-5) M) did not affect the high-K(+)-induced contractile response, it selectively inhibited the potentiating effect of LPC on the contraction and it strongly inhibited the LPC-induced augmentation of the associated increases in [Ca(2+)](i). Genistein also attenuated the LPC-induced augmentation effects on both the increase in [Ca(2+)](i) and contractile response induced by the UK14,304. In contrast, daidzein (10(-5) M) did not inhibit the potentiating effect of LPC. Tyrphostin B42 (3 x 10(-5) M) attenuated the potentiating effect of LPC on high K(+)-induced contractions. Western blot analysis showed that LPC increased the tyrosine phosphorylation of a number of proteins, including 42 and 44 kDa proteins and 53 - 64 kDa proteins. These protein phosphorylations were inhibited by genistein. Sodium orthovanadate (10(-4) M), a tyrosine phosphatase inhibitor, also markedly enhanced the high-K(+)-induced contractile responses. This enhancing effect was attenuated by genistein. These results suggest that the LPC-induced augmentation of contractile responses in the rat aorta is due to activation of tyrosine kinase, which in turn regulates Ca(2+) influx.
Suenaga
Hiroshi
H
Department of Physiology and Morphology, Institute of Medicinal Chemistry, Hoshi University, Shinagawa-ku, Tokyo 142-8501, Japan.
Kamata
Katsuo
K
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000201:enzymology* / Q000502:physiology; D000068438:Brimonidine Tartrate; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004789:Enzyme Activation / Q000187:drug effects; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019833:Genistein / Q000494:pharmacology; D008244:Lysophosphatidylcholines / Q000494:pharmacology*; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D010766:Phosphorylation / Q000187:drug effects; D011188:Potassium / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011810:Quinoxalines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014662:Vasoconstrictor Agents / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D004791:Enzyme Inhibitors; D008244:Lysophosphatidylcholines; D011810:Quinoxalines; D014662:Vasoconstrictor Agents; D000068438:Brimonidine Tartrate; D019833:Genistein; D011505:Protein-Tyrosine Kinases; D011188:Potassium